What is UroGen Pharma's cash ratio?

UroGen Pharma (URGN) reported cash ratio of 2.2× in Q1 2026.

How has UroGen Pharma's cash ratio changed year-over-year?

UroGen Pharma's cash ratio decreased by 12.3% year-over-year, from 2.5× to 2.2×.

What is the long-term trend for UroGen Pharma's cash ratio?

Over 5 years (2020 to 2025), UroGen Pharma's cash ratio has grown at a -0.7% compound annual growth rate (CAGR), from 2.5× to 2.4×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

UroGen Pharma URGN Cash ratio

Cash ratio at other companies

Bristol-Myers SquibbBMY

0.5×0.0×

PfizerPFE

0.1×0.0×

Johnson & JohnsonJNJ

0.4×-0.3×

Merck & Co.MRK

0.2×-0.1×

ImmunityBio, Inc.IBRX

3×+1.8×

Tyra Biosciences, Inc.TYRA

4.4×-2.7×

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

cash and equivalents/total current liabilities=2.2×

Based on the most recent quarter.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's cash ratio?: UroGen Pharma (URGN) reported cash ratio of 2.2× in Q1 2026.
How has UroGen Pharma's cash ratio changed year-over-year?: UroGen Pharma's cash ratio decreased by 12.3% year-over-year, from 2.5× to 2.2×.
What is the long-term trend for UroGen Pharma's cash ratio?: Over 5 years (2020 to 2025), UroGen Pharma's cash ratio has grown at a -0.7% compound annual growth rate (CAGR), from 2.5× to 2.4×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.